A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer

A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer - A Study on QOL, response and safety of eribulin for inoperable or recurrent breast cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010807

Enrollment

100

Registered

2013-05-26

Start date

2011-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inoperable or recurrent breast cancer

Interventions

eriburin mesylate 1.4mg/m2, days 1 and 8, q21 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with history of prior treatment with anthracycline and taxane. - Written informed consent was obtained

Exclusion criteria

Exclusion criteria: - patients with advanced bone marrow suppression. - patients who has an anamnesis of hypersensitivity to the ingredient of this agent. - pregnant women or the women that may have become pregnant - patients simultaneously treatmented by trastuzumab or lapatinib. - patients who judged that it was unsuitable as other candidates

Design outcomes

Primary

Measure	Time frame
The effect of improving the QOL(Quality of life) evaluated by the FACT-B	—

Secondary

Measure	Time frame
- OSS (objective response rate) evaluate by RECIST - Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026